Record orders, margin stumble—the risk is Q1 soft becomes Q2-Q4 softer
Revenue jumped 79% and the order book hit a record ₹61,500 Cr, but profit grew only 15%—and management held guidance rather than raising it. The quarter shows structural strength masked by near-term pressure that has to reverse in the second half.
79.2%
₹7,932 Cr delivered vs prior ₹4,424 Cr
15.4%
₹892 Cr delivered vs prior ₹773 Cr
18.1%
flat YoY, –6 bps QoQ
–20.8%
From ~₹1,126 Cr last quarter
Waaree delivered the headline growth story the street expected—revenue +79% YoY, module volumes +89% to 3.6 GW, order book at an all-time high of ₹61,500 Cr. On the surface, it is a textbook scaling play. But under the surface, the quarter reveals two stories in tension: a structural bull case intact, and a near-term stumble that management is not yet confident can be reversed.
The tension lives in the profit line. Revenue leapt 79%, but profit grew only 15%—a 64-percentage-point gap. That gap is earnings quality compression: raw material cost inflation, inventory build ahead of uncertain offtake, and softer-than-expected margins on the module base. Worse, profit actually fell 20.8% quarter-on-quarter, signaling that the growth narrative is decelerating fast once you strip out the YoY comps.
And the most telling sign: management reaffirmed FY27 operating EBITDA guidance of ₹7,000–7,700 Cr rather than raising it. That is the market's single biggest red flag. A record order book, a retail channel doubling at +130% YoY, and capex execution visible (APS deal closed, BESS live, 10 GW cell equipment in-house)—and yet no guidance bump. It tells you management sees H2 as a prove-it moment, not a coronation.
What the numbers actually say
Highest order book ₹61,500 Cr, up 23% QoQ
Confirmed; 10.2 GW module equivalent with 40% India, 36% U.S., 24% exports—well diversified
Supported
Revenue grew 79.2% YoY to ₹7,932 Cr
Delivered exact ₹7,932 Cr—no miss, no beat; matched guidance
Supported
Operating EBITDA 18.2% margin, up 44% YoY
Delivered 18.1% OPM (marginally lower); margin essentially flat YoY, compressed -6 bps QoQ
Overstated
Module volumes +89% YoY from 1.9 GW to 3.6 GW
YoY growth real, but production fell 14% quarter-on-quarter from 4.2 GW last Q—YoY growth narrative masks deceleration
Slightly overstated
Cell capacity 800 MW this quarter ramping to 1.5 GW by Q3-Q4
Equipment on-site, ALMM-II applied, timeline credible but ambitious; yield/integration risk real
Corroborated but execution-dependent
FY27 EBITDA guidance ₹7,000–7,700 Cr reaffirmed; cell ramp backs recovery
Q1 EBITDA ₹1,440 Cr implies ₹5,560–6,260 Cr needed Q2-Q4 (avg ₹1,853–2,087 Cr/Q). That is 29–45% above Q1 run-rate—doable but demanding
Corroborated but tight on execution
What changed on this call
Retail business inflecting faster than expected. Q1 retail revenue ₹2,289 Cr (+130% YoY vs ₹995 Cr prior year) annualizes to ₹9.2k Cr and sits comfortably inside the ₹9,000–10,000 Cr FY27 target. This is a genuine channel de-risking, reducing dependence on 5–10 large utilities.
Cell integration roadmap crystallizing. 10 GW cell equipment fully on-site, ALMM-II cleared. Cell-to-module integration to jump from 20% (now) to 65% by Q3–Q4. This is the structural margin lever: cell profitability at ₹0.04–0.05/Wp mfg cost but ₹0.12–0.13/Wp DCR market price; margin uplift to 35–41% once integrated vs 20–25% module-only.
U.S. tariff headwinds proved real and exports took the hit. Export revenue fell sharply Q1; management blamed 6-month market lull due to tariff confusion. U.S. order book is 25% of total. Recovery assumed Q2+ but not guaranteed. This is the biggest near-term wildcard.
The bull-bear ledger
Order book at ₹61,500 Cr is all-time high and provides 9–12-month visibility
Capex execution visible: APS 55% stake closed, BESS container live, cell equipment in-house, retail network deepening
Retail revenue doubling (+130% YoY) and moving toward ₹9–10k Cr run-rate de-risks concentration
Cell capacity ramp (5.4 GW → 15.4 GW by year-end) is the core margin lever; roadmap credible
Policy tailwinds real: DCR 100% by FY29, ALMM quota protection, PLI ₹1,920 Cr approved, wafer policy Jun 2028
Structural thesis intact: de-risking via backward integration, supply chain capture, retail, geography
But: PAT grew only 15% while revenue grew 79%—margin compression is severe and real
QoQ PAT fell 20.8% and module production fell 14% QoQ—the growth story is decelerating fast
Guidance reaffirmed not raised—management sees H2 as risky, not a coronation
Inventory build masking offtake risk; if H2 customer deferrals extend, working capital deteriorates
U.S. tariffs real and 6-month lull hit exports; 25% of order book is U.S. sales, vulnerable
Cell capacity ramp by Dec 2026 is ambitious; any yield/integration delay pushes margin inflection into FY28
Raw material cost inflation (polysilicon, glass, silicon) may not reverse quickly; margin recovery dependent on ramp+pricing
Risks, ranked by how much they should concern a holder
Cell capacity ramp and yield: 10 GW equipment online by Dec 2026, but ramping to full production within same quarter is aggressive. Yield issues or integration delays would push margin inflection into FY28.
HighFY27 EBITDA guidance depends on H2 cell contribution. If cell comes online late or yields fall, H2 EBITDA target becomes unachievable and FY28 guidance will need reset downward.
U.S. tariff headwinds persist or widen: 6-month market lull cited; recovery assumed Q2+ but tariff policy may not stabilize. 25% of order book is U.S. sales at ₹0.04–0.05/Wp margin—if tariffs widen further, margin erodes.
HighU.S. local manufacturing (1.6 GW) is the mitigation, but ramp is also dependent on Q2–Q3 execution. Any delay in local capacity or continued tariff uncertainty could force export deferrals into FY28.
Customer offtake timing: Non-DCR 6-month extension window critical; if offtake defers past Dec 2026, inventory pile-up extends working capital drag and margin compression into FY28.
MediumQ1 inventory built ahead of expected H2 dispatch. If H2 offtake misses, inventory will become a cash-flow drag and signal weakening customer confidence.
Policy withdrawal: ALMM/PLI/DCR removal or watering would crater realization tiers (₹0.12–0.13/Wp DCR vs $0.04–0.045 import). Structural but not guaranteed long-term.
MediumManagement argues policies are structural (like defence, electronics), but political risk is real. Any withdrawal would reset the margin thesis and force pricing power downward.
Capex execution: ₹31,500 Cr over 3 years across 6 business units (module, cell, wafer, T&D, BESS, inverter). Any single delay cascades; ROCE-accretion claims unproven.
MediumCapital intensity is high; if ROCE on capex falls below 12–15%, return on equity will deteriorate and funding needs (₹10k Cr QIP planned) will increase.
How the street is positioned
Price action is the market's own verdict: the stock fell 4.07% on day 1 post-result announcement (Jul 29) and has not recovered. It trades at ₹2,660.9 as of Aug 6, down 28.45% from its all-time high and below all key moving averages (SMA20 ₹2,748, SMA50 ₹2,902, SMA200 ₹3,019). The sell-off is telling: the record order book and capex execution were not enough to offset the margin miss and guidance hold.
Ownership tells a different story: FII have quietly been adding (7.05% in Q4 FY26 vs 0.70% in Q1 FY25—a 10x increase), suggesting institutional confidence in the structural bull case. But DII remain light (4.32%), and the lack of domestic institutional support is a yellow flag. Promoter ownership stable at 64.19%, so no insider selling pressure. The FII accumulation suggests long-term investors believe in the Waaree 2.0 thesis, but the DII silence and stock weakness suggest they are waiting for proof of H2 execution before adding.
Valuation compression is real: down 28% from ATH and trading below all SMAs, the stock has priced in execution risk. At current levels, if H2 cell ramp and offtake recovery materializes, the upside is significant (back to ATH, another 40%). If H2 disappoints, the downside is also significant (another 15–20% to test support below current lows). This is a binary setup: prove-it quarter.
What to watch next
1 · Cell capacity ramp: 800 MW → 1.2 GW by Q2-Q4
Cell production ramping is the core margin lever. Track quarterly cell volumes and yields; if they track guidance, margin recovery is credible. If they miss, FY27 EBITDA target is at risk.
2 · Module production stabilization and H2 offtake recovery
Module production fell 14% QoQ to 3.6 GW. Q2-Q4 should show a recovery to 4+ GW/Q as non-DCR offtake window opens (6-month extension through Dec). If production remains flat or falls further, it signals customer deferrals are extending into H2.
3 · Operating margin inflection: watch for 18.5%+ by Q3-Q4
Q1 OPM was 18.1%, flat YoY and -6 bps QoQ. Management guides for margin recovery in H2 via cell integration and capacity utilization. If Q2-Q3 OPM remains below 18%, cell ramp is not delivering margin accretion and the H2 recovery thesis is broken.
The honest read
Waaree's Q1 FY27 was a tale of two tensions: headline growth (+79% revenue, record order book) vs. near-term stumble (PAT +15%, QoQ PAT -20.8%, margin flat YoY, module production down QoQ, guidance held). The stock has repriced from ATH ₹3,718 to ₹2,661 (down 28%), and the street is split between long-term believers (FII 7.05%, quietly accumulating) and cautious near-term traders (DII light, stock below all SMAs).
The bull thesis—structural de-risking via cell integration, capex execution, retail ramp, and policy tailwinds—is intact and real. But it is now a hostage to H2 delivery. Management has one quarter to prove cell ramp (800 MW → 1.5 GW), module recovery (3.6 GW → 4+ GW/Q), and margin inflection (18.1% → 18.5%+) are achievable. If they are, the upside to ₹3,500+ is substantial. If they are not, the downside to ₹2,200 is also substantial. Until then, execution risk warrants a Hold.
Informational and educational content only. Not investment advice.